The Enterprise Value as of November 2024 (TTM) for Humacyte, Inc. (HUMA) is 559.17M

According to Humacyte, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 559.17M. This represents a change of 68.82% compared to the average of 331.21M of the last 4 quarters.

Humacyte, Inc. (HUMA) Historical Enterprise Value (quarterly & annually)

How has HUMA Enterprise Value performed in the past?

The mean historical Enterprise Value of Humacyte, Inc. over the last ten years is 136.41M. The current 559.17M Enterprise Value has changed 40.89% with respect to the historical average. Over the past ten years (40 quarters), HUMA's Enterprise Value was at its highest in in the March 2021 quarter at 1.12B. The Enterprise Value was at its lowest in in the December 2019 quarter at -92213000.00.

Humacyte, Inc. (HUMA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Humacyte, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Humacyte, Inc. (HUMA) Average Enterprise Value

How has HUMA Enterprise Value performed in the past?

The current Enterprise Value of Humacyte, Inc. (HUMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Humacyte, Inc. (HUMA) Enterprise Value vs. Peers

How is HUMA’s Enterprise Value compared to its peers?

Humacyte, Inc.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.87B), less than Viridian Therapeutics, Inc. (1.66B), less than Cytokinetics, Incorporated (6.66B), less than Structure Therapeutics Inc. (1.90B), less than Icosavax, Inc. (713.87M), less than Immunocore Holdings plc (1.53B), less than Mirum Pharmaceuticals, Inc. (2.01B), greater than Larimar Therapeutics, Inc. (453.31M), greater than KalVista Pharmaceuticals, Inc. (477.00M), greater than Lyra Therapeutics, Inc. (22.05M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Kura Oncology, Inc. (1.34B), less than Nurix Therapeutics, Inc. (1.70B), greater than Seer, Inc. (119.24M), greater than Quantum-Si incorporated (49.97M), greater than HCW Biologics Inc. (25.13M), greater than MediciNova, Inc. (38.55M),

Build a custom stock screener for Humacyte, Inc. (HUMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humacyte, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Humacyte, Inc. (HUMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Humacyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.